calendar
25,838 catalysts · 6,193 approval · 5,000 device 510k · 4,728 grant · 3,126 8k filing · 2,000 device pma · 2,000 device recall
next 91 dayslessmore
MonWedFri
25,838 catalysts · 6,193 approval · 5,000 device 510k · 4,728 grant · 3,126 8k filing · 2,000 device pma · 2,000 device recall
Sponsor: LANNETT CO INC. Form: TABLET. Route: SUBLINGUAL
Sponsor: LANNETT CO INC. Form: TABLET. Route: SUBLINGUAL
Sponsor: AMNEAL PHARMS. Form: TABLET. Route: SUBLINGUAL
Sponsor: AMNEAL PHARMS. Form: TABLET. Route: SUBLINGUAL
Sponsor: ACTAVIS ELIZABETH. Form: TABLET. Route: SUBLINGUAL
Sponsor: ACTAVIS ELIZABETH. Form: TABLET. Route: SUBLINGUAL
Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION
Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: STRIDES PHARMA. Form: TABLET. Route: ORAL
Sponsor: HIBROW HLTHCARE. Form: CAPSULE. Route: ORAL
Sponsor: GENENTECH. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS. Form: TABLET. Route: ORAL
Sponsor: NOVARTIS. Form: CAPSULE. Route: ORAL
Sponsor: AMNEAL PHARMS. Form: TABLET. Route: ORAL
Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: SOLUTION. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: SOLUTION. Route: ORAL
Sponsor: OSMOTICA PHARM US. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: PYROS PHARMS. Form: FOR SOLUTION. Route: ORAL
Sponsor: VIVUS LLC. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL
Sponsor: GILEAD SCIENCES INC. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: TORRENT PHARMS. Form: TABLET. Route: ORAL
Sponsor: TORRENT PHARMS. Form: TABLET. Route: ORAL
Sponsor: AVION PHARMS. Form: TABLET. Route: ORAL
Sponsor: INNOGENIX. Form: TABLET. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: TABLET. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: TABLET. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: TABLET. Route: ORAL
Sponsor: CELGENE CORP. Form: POWDER. Route: SUBCUTANEOUS
Sponsor: UMEDICA. Form: TABLET. Route: ORAL
Sponsor: TORRENT. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL
Sponsor: TORRENT. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL
Sponsor: TORRENT. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL
Sponsor: TORRENT. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL
Sponsor: TORRENT. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL
Sponsor: TORRENT. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL
Sponsor: CHATTEM SANOFI. Form: SOLUTION. Route: ORAL
Sponsor: TORRENT PHARMS LTD. Form: TABLET. Route: ORAL
Sponsor: TORRENT PHARMS LTD. Form: TABLET. Route: ORAL
Sponsor: TORRENT PHARMS LTD. Form: TABLET. Route: ORAL
Sponsor: TORRENT PHARMS LTD. Form: TABLET. Route: ORAL
Sponsor: TORRENT PHARMS LTD. Form: TABLET. Route: ORAL
Sponsor: TORRENT PHARMS LTD. Form: TABLET. Route: ORAL
Sponsor: HIKMA. Form: TABLET. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: TABLET. Route: ORAL
Sponsor: BIOCODEX SA. Form: CAPSULE. Route: ORAL
Sponsor: BIOCODEX SA. Form: FOR SUSPENSION. Route: ORAL
Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION
Sponsor: HETERO LABS LTD V. Form: TABLET. Route: ORAL
Sponsor: EXELIXIS INC. Form: TABLET. Route: ORAL